Annovis Bio, Inc. (ANVS) Form 8-K — May 15, 2026
Annovis Bio reported a net loss of $17.6 million for the first quarter of 2026, driven by a sharp increase in R&D expenses to $16.7 million from $5.0 million year-over-year as it accelerates enrollment in its pivotal Phase 3 Alzheimer’s trial. The company has reached 85% enrollment in its Phase 3 AD study and expects to complete randomization in summer 2026, with first top-line results anticipated in early 2027. It also launched an open-label extension study for Parkinson’s disease, which is 40% enrolled. Cash and cash equivalents stood at $14.2 million as of March 31, 2026, excluding $10.0 million in gross proceeds from a registered direct offering completed in April 2026.
Key figures
- Revenue
- 0
- Total Debt
- 0
- Total Assets
- 16243703
- Cash Position
- 14219081
- Shares Outstanding
- 28537302
- Ga expense q1 2025
- 1271164
- Ga expense q1 2026
- 1291820
- Rd expense q1 2025
- 5011517
- Rd expense q1 2026
- 16720362
- Recent capital raise
- 10000000
- Pd ole enrollment pct
- 40
- Ad trial enrollment pct
- 85
Price after filing
Close on the filing date to close N calendar days later (from $2.13). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.